OBJECTIVE: To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer's disease. DESIGN: A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Iran. METHODS:Patients with mild to moderate Alzheimer's disease aged between 65 and 80 years (n = 42; 18 women, 24 men) with a score of >or= 12 on the cognitive subscale of Alzheimer's disease assessment scale (ADAS-cog) and <or= 2 on the clinical dementia rating (CDR) were randomised to placebo or fixed dose of Melissa officinalis extract. The main efficacy measures were the change in the ADAS-cog and CDR-SB scores compared with baseline. Side effects were systematically recorded. RESULTS: At four months, Melissa officinalis extract produced a significantly better outcome on cognitive function than placebo (ADAS-cog: df = 1, F = 6.93, p = 0.01; CDR: df = 1, F = 16.87, p < 0.0001). There were no significant differences in the two groups in terms of observed side effects except agitation, which was more common in the placebo group (p = 0.03). CONCLUSIONS:Melissa officinalis extract is of value in the management of mild to moderate Alzheimer's disease and has a positive effect on agitation in such patients.
RCT Entities:
OBJECTIVE: To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer's disease. DESIGN: A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Iran. METHODS:Patients with mild to moderate Alzheimer's disease aged between 65 and 80 years (n = 42; 18 women, 24 men) with a score of >or= 12 on the cognitive subscale of Alzheimer's disease assessment scale (ADAS-cog) and <or= 2 on the clinical dementia rating (CDR) were randomised to placebo or fixed dose of Melissa officinalis extract. The main efficacy measures were the change in the ADAS-cog and CDR-SB scores compared with baseline. Side effects were systematically recorded. RESULTS: At four months, Melissa officinalis extract produced a significantly better outcome on cognitive function than placebo (ADAS-cog: df = 1, F = 6.93, p = 0.01; CDR: df = 1, F = 16.87, p < 0.0001). There were no significant differences in the two groups in terms of observed side effects except agitation, which was more common in the placebo group (p = 0.03). CONCLUSIONS:Melissa officinalis extract is of value in the management of mild to moderate Alzheimer's disease and has a positive effect on agitation in such patients.
Authors: D A Evans; H H Funkenstein; M S Albert; P A Scherr; N R Cook; M J Chown; L E Hebert; C H Hennekens; J O Taylor Journal: JAMA Date: 1989-11-10 Impact factor: 56.272
Authors: Farida Larit; Khaled M Elokely; Narayan D Chaurasiya; Samira Benyahia; Manal A Nael; Francisco León; Mohammad Sanad Abu-Darwish; Thomas Efferth; Yan-Hong Wang; Djamila Belouahem-Abed; Samir Benayache; Babu L Tekwani; Stephen J Cutler Journal: Phytomedicine Date: 2017-12-27 Impact factor: 5.340
Authors: Clive G Ballard; Serge Gauthier; Jeffrey L Cummings; Henry Brodaty; George T Grossberg; Philippe Robert; Constantine G Lyketsos Journal: Nat Rev Neurol Date: 2009-05 Impact factor: 42.937
Authors: Alison R Anderson; Jie Deng; Robert S Anthony; Sebastian A Atalla; Todd B Monroe Journal: Crit Care Nurs Clin North Am Date: 2017-09-27 Impact factor: 1.326